Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation

MT Newswires Live10-15

Immuneering (IMRX) said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.

The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.

The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.

Shares of Immuneering advanced 23% in premarket activity Tuesday.

Price: 2.4600, Change: +0.46, Percent Change: +23.00

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475330500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475330500","market":"us","top_or_hot":-1,"title":"Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation","media":"MT Newswires Live","content":"<html><body><p> Immuneering (IMRX) said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.</p><p>The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.</p><p>The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.</p><p>Shares of Immuneering advanced 23% in premarket activity Tuesday.</p><p>Price: 2.4600, Change: +0.46, Percent Change: +23.00</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 21:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immuneering (IMRX) said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.The company ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMRX","symbol_name":"Immuneering Corp","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475330500","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475330500","pubTimestamp":1728998166,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immuneering  said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.Shares of Immuneering advanced 23% in premarket activity Tuesday.Price: 2.4600, Change: +0.46, Percent Change: +23.00","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMRX":"Immuneering Corp","BK4563":"昨日强势股","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Immuneering表示潜在的胰腺癌治疗方法获得FDA孤儿药称号","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRX":1},"content_text":"Immuneering (IMRX) said Tuesday that its investigational drug IMM-1-104 has received orphan drug designation from the US Food and Drug Administration in the treatment of pancreatic cancer.The company said a phase 2a clinical trial to evaluate IMM-1-104 combined with chemotherapy in patients with advanced solid tumors, including pancreatic cancer, is ongoing.The company, which recently announced positive initial phase 2a results, said it expects to provide initial data from at least one additional arm of the phase 2a portion of its phase 1/2a trial before the end of the year.Shares of Immuneering advanced 23% in premarket activity Tuesday.Price: 2.4600, Change: +0.46, Percent Change: +23.00","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475330500"}